China’s CF PharmTech raises $90m Series E led by New Alliance Capital

Chinese pharma company CF PharmTech, Inc has raised $90 million in its Series E round led by New Alliance Capital, according to a statement.

The round saw participation from CR-CP Life Science Fund, Finnova Capital, GT Capital, Co-stone Asset Management, Xiangcheng Financial Holdings and Everest Venture Capital. Return backers, Oriza Holdings, Longmen Venture Capital, GTJA Investment and CMB International, too joined the round.

“The completion of this round of funding reflects the strong support from China’s investors to fuel high-caliber pharmaceutical companies that have a strong global competitive edge, and will allow CF PharmTech to bring products in its pipeline to market,” the company said in the statement.

CF PharmTech, which specialises in respiratory health, has set up state-of-the-art R&D and manufacturing facilities for inhalation products.

The company claims that it has a growing pipeline of over 20 products targeting China and global markets.

CEC Capital served as the exclusive financial adviser to CF PharmTech on the deal.

Recently, Chinese precision medicine startup Geneseeq closed 800 million yuan ($114 million) in a Series D round of financing led by state-owned China Reform Holdings Corporation.

Earlier, Shanghai Kechow Pharma, a small molecule drug development company, had raised 313 million yuan ($45 million) in its Series C round led by Decheng Capital.

Meanwhile, EOC Pharma, an oncology-focused biopharmaceutical company secured nearly 500 million yuan ($71 million) in a Series C round of financing led by Tigermed, TF Capital, and Yingke PE.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.